Market cap
$214 Mln
Recently Viewed
Clear All$0.81
$0.01
(0.74%)
As on 30-Apr-2026 11:39EDT
Market cap
$214 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
0
P/B Ratio
0.1
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
1.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.5
Debt to Equity
0
Book Value
$40.3
EPS
$25.7
Face value
--
Shares outstanding
241,048,724
CFO
$-125.72 Mln
EBITDA
$-131.81 Mln
Net Profit
$-153.73 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Enlivex Therapeutics - ADR
| 14.8 | -23.1 | -29.8 | -22.8 | -34.2 | -41.8 | -37.6 |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Enlivex Therapeutics - ADR
| -39.9 | -31.4 | -37.0 | -25.9 | 0.5 | 35.6 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Enlivex Therapeutics - ADR
|
0.8 | 214.2 | 0.0 | 1,235.5 | -- | 126.2 | 0 | 0.1 |
| 0.4 | 6.0 | 2.4 | -11.5 | -475.0 | -117.6 | -- | 1.0 | |
| 2.6 | 293.1 | 72.8 | 35.3 | 0.0 | 44.8 | 8.2 | 2.7 | |
| 0.8 | 9.5 | 3.9 | -8.5 | -318.9 | 1107 | -- | 6.2 | |
| 0.6 | 4.1 | 0.0 | -10.3 | -- | -64.2 | -- | 0.3 | |
| 71.4 | 242.8 | 19.4 | -6.1 | -30.2 | -23.7 | -- | 10.6 | |
| 23.4 | 1,173.7 | 109.8 | -153.5 | -125.8 | 268.6 | -- | 19.3 |
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM... intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel. Read more
Executive Chairman
Mr. Shai Novik M.B.A.
Executive Chairman
Mr. Shai Novik M.B.A.
Headquarters
Ness Ziona
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Enlivex Therapeutics Ltd - ADR is $0.81 (NASDAQ) as of 30-Apr-2026 11:39 EDT. Enlivex Therapeutics Ltd - ADR has given a return of -34.25% in the last 3 years.
The P/E ratio of Enlivex Therapeutics Ltd - ADR is 0.03 times as on 24-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.03
|
0.02
|
|
2024
|
-1.64
|
1.04
|
|
2023
|
-1.76
|
1.71
|
|
2022
|
-2.28
|
1.25
|
|
2021
|
-7.78
|
1.32
|
The 52-week high and low of Enlivex Therapeutics Ltd - ADR are Rs 2.10 and Rs 0.66 as of 30-Apr-2026.
Enlivex Therapeutics Ltd - ADR has a market capitalisation of $ 214 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Enlivex Therapeutics Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.